DOV 216303

Known as: DOV 216,303 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2014
012320032014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Peripheral administration of lipopolysaccharide (LPS) in rodents induces anhedonia, i.e. the inability to experience pleasure… (More)
Is this relevant?
2014
2014
DOV 216,303, an inhibitor of serotonin, noradrenaline and dopamine reuptake, belongs to a new line of drugs called 'triple… (More)
Is this relevant?
2012
2012
Monoamine reuptake inhibitors increase brain-derived neurotrophic factor (BDNF) activity, and this growth factor is regarded as… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
Triple reuptake inhibitors (TRIs) are potential new antidepressants, which not only enhance brain serotonin and norepinephrine… (More)
Is this relevant?
2011
2011
DOV 216,303 belongs to a new class of antidepressants, the triple reuptake inhibitors (TRIs), that blocks serotonin… (More)
Is this relevant?
2010
2010
Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2010
2010
The first line of antidepressant treatment nowadays are selective serotonin reuptake inhibitors. Although they are relatively… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Current antidepressants have a delayed onset of action and disturbing side effects, including inhibition of sexual behavior. It… (More)
Is this relevant?
2008
2008
The goal of this study was to develop and validate ex vivo binding assays for serotonin (SERT), norepinephrine (NET) and dopamine… (More)
Is this relevant?
2004
2004
This report describes the first evaluation in humans of DOV 216,303, a putative antidepressive that inhibits the reuptake of… (More)
Is this relevant?